← Evidence map

TrialDiabetes care2012

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Julio Rosenstock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

171 papers cite itlatest 60 shown

2012
…
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 22492586